Scientific Literature Review: Tesamorelin

Compiling a literature review on Tesamorelin for community reference. I have gone through PubMed and pulled the most relevant publications. Total published studies referencing Tesamorelin: dozens, ranging from basic science to clinical trials. The quality varies considerably, with some well-designed RCTs and many smaller observational studies and case reports. Mechanism studies: the receptor pharmacology of Tesamorelin is well-characterized. Multiple groups have independently confirmed the binding profile and downstream signaling pathways. This is actually a strength of the evidence base — independent replication increases confidence. Efficacy studies: the clinical trial data shows consistent moderate effects on primary endpoints related to recovery, tissue repair, and relevant biomarkers. Effect sizes in the range of 15-30 percent improvement over placebo are typical, which is clinically meaningful. Safety studies: Tesamorelin has a clean safety record in published literature. The incidence of adverse events is low and severity is mild. No dose-limiting toxicities have been identified within the studied dose ranges. Gaps in the literature: we need more long-duration studies, more diverse study populations, and more head-to-head comparisons with alternative approaches. The existing data is encouraging but incomplete. I maintain a running list of key papers and will share it in the comments for anyone who wants to do their own reading.